RBC Capital analyst Gregory Renza maintained a Buy rating on Aptose Biosciences (APTO – Research Report) on March 22 and set a price target of $7.00. The company’s shares closed last Wednesday at $1.22, close to its 52-week low of $1.00.
According to TipRanks.com, Renza is a 1-star analyst with an average return of -2.0% and a 40.0% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Verrica Pharmaceuticals, and Pacira Pharmaceuticals.
Aptose Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $7.73, implying a 549.6% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a C$12.00 price target.
Based on Aptose Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.33 million. In comparison, last year the company had a GAAP net loss of $13.25 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
Read More on APTO: